AASLD 2013博客 ：为什么越来越多的研究表明拉米夫定，不应该

StephenW

Blog
Monday, November 4, 2013
AASLD 2013: More Studies Show Why Lamivudine Should No Longer Be Used


— Christine M. Kukka, Project Manager, HBV Advocate

More Studies Show Why Lamivudine Should No Longer Be Used

    Lamivudine a poor choice for lowering viral load in pregnant women: Twenty-one women with high viral load were treated with lamivudine for about 53 days toward the end of their pregnancies. None transmitted the infection to their newborns, but they had only modest reductions in viral load and four women developed some form of drug resistance.

    Control ID 1735799. Short duration of lamivudine for prevention of HBV transmission in pregnancy: Lack of potency and selection of resistance mutations. (Abstract #1018)

    Lamivudine treatment ineffective in cirrhotic patients, compared to other antivirals. Korean researchers followed 1,824 patients treated with either lamivudine or entecavir for more than five years and found that cirrhotic patients treated with entecavir had markedly lower rates of liver transplants or death from liver disease than those treated with lamivudine.

    Control ID 1735949. Comparative effectiveness of entecavir and lamivudine on survival of patients with chronic hepatitis B virus infection. (Abstract #32)

为什么越来越多的研究表明拉米夫定，不应该再使用

    拉米夫定降低病毒载量孕妇一个糟糕的选择：二十一妇女高病毒载量与拉米夫定治疗快要结束其怀孕约53天。无传播感染的新生儿，但他们只有适度减少病毒载量和四名妇女发展某种形式的耐药性。

    控制ID 1735799 。拉米夫定预防乙肝病毒传播在怀孕时间短：缺乏效力和耐药突变的选择。 （摘要编号1018 ）

    拉米夫定治疗无效的肝硬化患者，相比其他抗病毒药物。韩国研究人员跟踪调查了1,824无论是拉米夫定或恩替卡韦五年以上的患者发现，肝硬化患者使用恩替卡韦治疗有显着较低的利率比那些用拉米夫定治疗肝病肝移植或死亡。

    控制ID 1735949 。恩替卡韦和拉米夫定治疗慢性乙肝病毒感染的患者生存的比较效益。 （摘要编号32 ）